The induction of tumor-specific immune responses is largely dependent on the ability of dendritic cells (DCs) to present tumor-associated antigens to T lymphocytes. Therefore, we investigated the use of DC-associated promoter-driven genetic vaccines to specifically target DC in vivo. Restricted expression of vaccine-encoding genes in DC should enhance specificity and improves their safety for clinical applications. Hereto, 3 --5 kb upstream sequences of the murine genes encoding CD11c, DC-SIGN, DC-STAMP and Langerin were isolated, characterized and subcloned into enhanced green fluorescent protein (EGFP) reporter constructs. Upon electroporation, EGFP was expressed in DC cell lines, but not in other cell lines, confirming DCrestricted promoter activity. When these promoters were cloned into a construct upstream of the gene for ovalbumin (OVA), it appeared that DC-STAMP promoter-driven expression of OVA (pDCSTAMP/OVA) in DC yielded the most efficient OVA-specific CD4 þ and CD8 þ T-cell responses in vitro. Administration of pDC-STAMP/OVA in vivo, using the tattoo gun vaccination system, evoked specific immune responses as evidenced in a mouse tumor model. Adoptively transferred pDC-STAMP/OVA-transfected DCs induced strong CD8 þ T-cell proliferation in vivo. These experiments demonstrate that our DC-directed promoter constructs are potential tools to restrict antigen expression in DC and could be implemented to modulate DC function by the introduction of relevant proteins.
INTRODUCTION
Dendritic cells (DCs) are the most potent antigen presenting cells of the immune system. DCs reside in an immature stage in nearly all peripheral tissues where they capture, process and present local antigens. Upon encountering pathogens, DCs mature, migrate to draining lymph nodes and prime T lymphocytes. 1 Because of their essential role in catalyzing the adaptive immune response, DCs are currently exploited in tumor immunotherapies. One method to direct DC responses for tumor immunotherapy is to use DNA vaccination combined with DC-specific promoters to transcriptionally target protein expression to DCs. These proteins could be, for instance, cytokines, growth factors or signal transducers and they would ultimately have the ability to alter the activation state of the DCs. This technology also allows expression of tumor antigens directly by DCs for the induction of antigen-specific immune responses, and limiting vaccine antigen expression to DCs could also improve its safety for clinical applications.
Following DNA vaccination using a broadly and highly active promoter, such as cytomegalovirus (CMV) immediate early promoter (pCMV), antigens are delivered to DCs through either cross-presentation or direct antigen expression by DCs. Several studies indicate that the latter method is mainly responsible for antigen presentation in the lymph nodes. 2, 3 It was shown that during cutaneous DNA vaccination, in vivo transfected DCs that directly express target antigens were primarily responsible for the activation of CD4 þ and CD8 þ T cells, as opposed to DCs cross-presenting antigen. Several ways of cutaneous DNA delivery have been reported, ranging from the tape stripping, lipidmediated and nanoparticles-mediated transfer to needle-free electorporation, gene gun and tattoo. 4 --18 The availability of antigen produced by transfected keratinocytes, despite being produced abundantly, was limited unless apoptosis of the keratinocytes was induced. 2 Thus, it appears that sufficient targeting of DCs is crucial for the development of antigen-specific responses as a result of DNA vaccination.
To date, a few DC-specific promotors have been used to transcriptionally target DCs. 17,19 --21 Despite the transfection of very few cells, Ross and co-workers 21 were able to detect strong antigen-specific Th1 responses and these responses could undermine the development of Th2 responses in an in vivo allergy model. Nevertheless, anti-tumor immunity, involving the T-cell responses or even tumor rejection, has yet to be demonstrated after DNA vaccination with constructs carrying DC-specific promotors. Recently, the 5 0 untranslated region of DC-STAMP gene was successfully used in lentiviral vectors yielding long-term and cell-selective transgene expression in vivo. 13 In order to develop additional vectors for permissive expression in DCs in vitro and in vivo with protein, the promoters of the murine genes encoding cd11c, dc-sign, 22 dc-stamp 23 and langerin 24 were cloned. We demonstrated that the DNA sequences that we cloned were primarily active in the DC cell lines, D1, and differentiated Raw 264.7 cells. All four promoters driving ovalbumin (OVA) expression in DCs lead to specific CD8 þ T-cell proliferation in vitro. Using the pDC-STAMP/OVA construct, it was shown that DC-STAMP promoter-driven OVA expression in DCs was exceptional in that it could induce CD4 þ as well as CD8 þ T-cell responses. Further, experiments with pDC-STAMP/OVA demonstrated in vivo potential as pDC-STAMP/OVA-transfected DCs were functional after adoptive transfer and tumor progression in the B16OVA melanoma model was hindered after tattoo vaccination. Our results confirm that DC-associated promoters can successfully drive gene expression in DCs. Moreover, besides being potential tools to target tumor antigens to DCs, our promoters could be relevant tools to modify DC function by the introduction of other effector proteins like cytokines and signal transducers.
MATERIALS AND METHODS Animals
Female C57Bl/6N mice (Charles River Wiga, Sulzfeld, Germany) were obtained at 6 --8 weeks of age. OVA-specific TCR-transgenic OT-I and OT-II mice were bred at the Central Animal Laboratory located at the Radboud University Nijmegen Medical Centre (Nijmegen, The Netherlands). Animals were maintained under specific pathogen-free barrier conditions at the Central Animal Laboratory (Nijmegen, the Netherlands) and the experiments were performed in accordance to the guidelines for animal care of the Nijmegen Animal Experiments Committee. Dr Paola Ricciardi-Castagnoli) was maintained in culture as previously described. 25 The B3Z T-cell hybridoma 26 and the OVA-transfected, murine melanoma cell line, B16OVA, 27 (derived from B16F10, clone MO5) was kindly provided by Dr Kenneth Rock. The medium used for the in vitro T-cell stimulation was RPMI 1640 supplemented with 5% FCS, glutamine, 50 mM b-Mercaptoethanol and antibiotics/antimycotics. All transfections were performed using the Amaxa Nucleofector system (Amaxa, Cologne, Germany). Please see Table 1 for details regarding the amount of cells and the transfection conditions used.
Cell lines and transfections

Vector constructs and plasmid isolation
The promoter sequences of murine cd11c, dc-sign, dc-stamp and langerin genes were determined using the Celera Database following an alignment with the corresponding cDNA. Using the primers sets described in Table 2 and the Expand Long Template PCR system (Roche diagnostics, Mannheim, Germany), 3 --5 kb sequences upstream from the starting codon of the genes were amplified from C57BL/6N genomic DNA and subcloned into the multiple cloning site of the promoter-less enhanced green fluorescent protein (pEGFP)-1 vector (GenBank Accession: #U55761; Clontech, Saint-Germain-en-Laye, France). All constructs were checked by sequencing at the sequencing facility of the Department of Human Genetics, Radboud University Nijmegen Medical Centre, and compared with publicly available sequences. During PCR, restriction enzyme sites were introduced into the primers (see Table 2 for a list) and were used to insert the fragments into the multiple cloning site. The CMV promoter was isolated from the pEGFP-N3 vector (GenBank Accession: #U57609; Clontech) and inserted in the multiple cloning site of pEGFP-1. The bovine keratin 5 promoter 28 was amplified from a plasmid, kindly provided by Dr JL Jorcano, using primers introducing SalI and XmaI sites at the 5 0 and 3 0 ends, respectively. The amplified fragment was further digested with SalI/ AgeI restriction enzymes and inserted into the multiple cloning site of the pEGFP-1 reporter system. The sequence coding for the full length of the chicken OVA was amplified from the pMFG/OVA plasmid, kindly provided by Dr Kris Thielemans, using the primer sets described in Table 2 . Subsequently, the coding sequence of EGFP was replaced by the OVAcoding sequence using AgeI/NotI sites. The plasmids were propagated in the Escherichia coli strain DH10 and purified from overnight cultures using either the Qiagen Plasmid or the EndoFree Plasmid kits (Qiagen, Venlo, The Netherlands) according the manufacturer's instructions. After DNA precipitatation, it was resuspended in pyrogen-free water and stored at À20 1C. 
Transcriptional targeting of dendritic cells V Moulin et al
Promoter analysis
Upstream promoters of cd11c, dc-sign, dc-stamp and langerin were analyzed for the possible presence of transcription factor binding sites (TFBSs) using the program P-match (http://www.gene-regulation.com/ cgi-bin/pub/programs/pmatch/bin/p-match.cgi) that scans input sequence with mononucleotide weight matrices as well as sets of aligned known TFBS from the TRANSFAC database (version 7.0 Public). Only high-quality matrices were used in the screen and only those having minimal sums for false-positive and false-negative error rates were included. Additionally, the promoter sequences were also analyzed for the presence of preselected enhancer elements using the program MacVector (version 7.0, MacVector, Cary, NC). These selected enhancer elements are consensus sequences rather than weight matrices and only exact matches were considered.
RNA isolation and reverse transcriptase PCR Naïve OVA-specific CD4 þ (OT-II) and CD8 þ (OT-I) T cells were isolated from spleen and inguinal lymph nodes using magnetic assisted cell sorting (Miltenyi Biotec, Auburn, CA). OT-I cells were first stained with anti-CD8b.2 FITC (BD PharMingen, Alphen aan den Rijn, The Netherlands) and then incubated with anti-FITC magnetic assisted cell sorting beads. OT-II cells were positively selected by use of directly-labeled anti-CD4 magnetic assisted cell sorting beads. Following isolation of the T-cell subsets, the cells were stained with carboxyfluorescein diacetate succinimidyl ester (CFSE) (Molecular Probes Europe BV, Leiden, The Netherlands) at a concentration of 0.5 mM in 1% FCS/phosphate-buffered saline for 10 min at 37 1C in the dark. Staining was stopped by the addition of pure FCS and the cells were then washed with medium. In all, 2 Â 10 5 CFSE-stained OT-I or OT-II were cultured in round-bottom 96-well plates with varying amounts of D1 cells, transfected 6 h earlier, with either irrelevant DNA (pCMV/EGFP) or pCMV/À, pK5/À, pCD11c, pDC-SIGN/À, pDC-STAMP/À or pLangerin/OVA constructs. OT-I or OT-II cell proliferation was measured by CFSE dilution at 48 and 96 h, respectively, after the beginning of the coculture.
Immunization protocol and induction of melanoma After shaving, mice were tattooed three times (day 0, 3 and 7) for 20 s on the left leg, using a Swiss Rotary Machine Mark II tattoo machine equipped with Radical Clean Magnum 11-needle bars (B.S. Trading B.V., Amsterdam, The Netherlands). This technique of dermal DNA vaccination has been previously described. 29 DNA vaccinations were performed with 15 mg of pCMV/EGFP as irrelevant DNA, 15 mg of pCMV/OVA or 30 mg of pDC-STAMP/OVA. At day 8, 15 000 OVA-transfected B16OVA tumor cells were injected subcutaneously into the left flank. Tumor growth was monitored three times per week and mice were killed when the tumor reached a width of 13 mm.
Detection of OVA-specific T cells
Cell suspensions were stained in ice-cold phosphate-buffered saline supplemented with 2 mM EDTA, 1% bovine serum albumin and 0.02% sodium azide (fluorescent-activated cell sorting buffer). The monoclonal antibody against CD11c (clone HL3), anti-CD4 and anti-CD8a were all obtained from BD Biosciences (Erembodegem-Aalst, Belgium). H-2 K b /OVA Tetramers detecting CD8 þ T cells specific for OVA peptide (257 --264; Pelimers, Sanquin, Amsterdam, The Netherlands) were used as previously described. 30 
RESULTS
The promoters for cd11c, dc-sign, dc-stamp and langerin contain TFBSs involved in DC development and function As DCs are pivotal to the development of immune responses during DNA vaccination, we cloned a variety of promoters preferentially targeting antigen production in DCs. To this end, we first characterized selected promoter sequences 3 --5 kb upstream from the DC-associated genes, cd11c, dc-sign, dc-stamp and langerin, using bioinformatics. As shown in Figure 1 , the analysis revealed the presence of several TFBSs that may have a role in myeloid function and/or differentiation. Binding sequences for c-Rel and AP1 were found extensively throughout all the promoters. Additional DC-associated TFBS, such as SPI1 and YY1, were included only if they conformed to the criteria of highquality matrices or exactly matched selected consensus sequences (see Materials and Methods for details). These analyses confirmed that 3 --5 kb upstream of the start codon for our chosen DCassociated genes contained multiple promoter elements necessary to confer DC-directed activity.
The promoters for cd11c, dc-sign, dc-stamp and langerin are preferentially active in DC cell lines In order to examine the selected promoters for DC specificity, we obtained several non-DC and DC cell lines. NIH3T3 fibroblasts and the macrophage cell line Raw 264.7 were used as non-DC cell lines. D1, the murine DC cell line, and Raw 264.7 cells treated with murine recombinant GM-CSF and IL-4 were used as example DC cell lines. As shown in Figure 2a , untreated Raw cells did not express CD11c, whereas an increased CD11c expression was observed (±60% of cells are CD11c-positive) upon their treatment with recombinant GM-CSF and IL-4 for 4 days. The DC specificity of our promoter sequences was first examined by determining the expression of endogenous genes from which the promoters were later isolated. No endogenous mRNA encoding cd11c, dc-sign, dcstamp (full length and splice variant) and langerin was detectable in untreated or GM-CSF/IL-4-treated NIH3T3 cells (Figure 1b) . Raw 264.7 cells did express low levels of cd11c, dc-stamp and langerin. However, their expression was upregulated following treatment with GM-CSF and IL-4, confirming differentiation towards a DC-like phenotype. No endogenous mRNA encoding dc-sign was detectable in Raw 264.7 cells regardless of cytokine treatments. As expected, D1 cells endogenously expressed all the four genes even after maturation with lipopolysaccharide. These results indicate that these genes are preferentially expressed within DC cell types and are likely good candidates for transcriptional targeting of DCs.
Next, the DC-associated 3 --5 kb upstream promoter sequences were cloned into vectors encoding EGFP and analyzed following transfection (Figure 2c ). The bovine keratin 5 promoter (pK5), known to be active in epidermal murine cells, 28 was also cloned in the same plasmid backbone for use as a negative control. Using the Amaxa Nucleofector system, we electroporated DC cell lines (GM-CSF/IL-4-treated Raw 264.7 and D1 cells) and non-DC cell lines (NIH3T3 fibroblasts and untreated Raw 264.7 cells) with constructs containing the DC promoters driving expression of the EGFP reporter. As a positive control, a construct containing the ubiquitous CMV promoter was also used. Figure 2d shows that 55.39% of pCMV/EGFP-transfected NIH3T3 were EGFP þ , whereas only very few EGFP þ NIH3T3 were detected after their transfection with the negative control (pK5/EGFP construct) or the pDC-SIGN/À, pDC-STAMP/À or pLangerin/EGFP plasmids. Surprisingly, pCD11c/EGFP was active within NIH3T3 cells (approximately 14%). The treatment of NIH3T3 cells with GM-CSF and IL-4 did not affect the EGFP expression driven by most of the promoters, except pCD11c, which showed a slight increase. A similar EGFP expression pattern was observed in untreated Raw 264.7 cells (Figure 2e) , however, after the differentiation of Raw 264.7 cells towards a DC phenotype using IL-4 and GM-CSF, a significantly increased activity of pCD11c (1.7-fold), pDC-SIGN (3.6-fold) and pDC-STAMP (4.2-fold) was seen. As displayed in Figure 2f , all DC promoters were able, to a varying degree, to drive EFGP expression in D1 cells. Furthermore, the mean fluorescence intensity of the EGFP expression, which gives an indication of the amount of the antigen produced per cell, indicated that pDC-STAMP was the most active of all the DC-associated promoters (Figure 2g ). Taken together, these data demonstrate that the four isolated DC-associated promoters contain the essential elements to confer DC-specific expression and are active within our DC cell lines.
OVA production via pDC-STAMP activates both OVA-specific CD8 þ and CD4 þ T cells Next, we examined whether antigens, expressed under the control of promoters that are preferentially active in DCs, are processed and presented to T cells and are capable of initiating specific immune responses. For this purpose, the coding sequence for the protein EGFP was replaced by a sequence coding the foreign antigen OVA (full length). Using these new constructs, D1 cells were transfected and tested for their capacity to activate the OVAspecific hybridoma B3Z. The B3Z T-cell hybridoma contains a lacZ reporter under the control of the il-2 promoter. Upon engagement of its TCR, which recognizes the OVA peptide (257 --264) in the context of H-2k b IL-2 is produced along with b-Galactosidase. 26 As a negative control, the same constructs were also transfected into murine embryonic fibroblasts expressing H-2k b The pCMV/OVAtransfected murine embryonic fibroblast cells were able to induce IL-2 production in the B3Z cells (Figure 3a) . However, none of the OVA constructs were capable of activating IL-2 production in this non-DC cell line. In contrast, all of the constructs transfected into D1 cells were able to activate B3Z cells (Figure 3b) . The pDC-STAMP/OVA plasmid was the most efficient of all the DC promoters in inducing IL-2 production.
We then tested the capacity of D1 cells, transfected with distinct DC-promoter/OVA constructs, to induce the in vitro proliferation of naïve CD8 þ (OT-I) and CD4 þ (OT-II) OVA-specific T cells. OT-I and OT-II T cells, isolated from spleen and inguinal LN, were labeled with CFSE and cultured with D1 cells electroporated with the various DC promoter/OVA constructs. As a positive control, D1 cells were transfected with pCMV/OVA, whereas pK5/OVA and pCMV/EGFP were used as negative controls. The DC promoter/ OVA constructs induced OT-I division to the same degree as the positive control pCMV/OVA (Figure 4a ). The negative control constructs, pK5/OVA and pCMV/EGFP, only induced background levels of OT-I cell proliferation.
The activation of the naïve OVA TCR-transgenic CD4 þ T cells (OT-II) was detectable at 96 h and required more electroporated D1 cells as compared with the stimulation required for the OT-I. Of the DC promoters, only pDC-STAMP was able to induce OT-II T-cell proliferation (Figure 4b) . However, the amount of dividing cells induced by pDC-STAMP/OVA (67.91%) was lower than that of dividing OT-II cells following their stimulation with pCMV/OVAtransfected D1 (80.05%). The other DC promoter constructs, pCD11c/-, pDC-SIGN/-and pLangerin/OVA, only induced OT-II proliferation comparable to the negative control constructs pK5/ OVA and pCMV/EGFP. Together, these results reveal that all the promoters preferentially active in DCs were able to drive antigen expression and thereby activate in vitro the proliferation of naïve antigen-specific CD8 þ T cells. However, only pDC-STAMP was capable of inducing detectable levels of OVA-specific CD4 þ T-cell activation.
Adoptive transfer of pDC-STAMP/OVA-transfected D1 leads to CD8 þ T-cell expansion in vivo As pDC-STAMP/OVA induced proliferation of both CD4 þ and CD8 þ T cells in vitro, we set out to examine the activity of this construct in vivo. To achieve this, we first transfected D1 cells in vitro with pDC-STAMP/OVA and then transferred these cells to mice containing 5 (and 6)-CFSE-labeled OT-I cells to examine the ability of these transfected D1 cells to stimulate proliferation in vivo. As positive controls, mature D1 cells loaded with the OVA peptide (257 --264) and pCMV-OVA-transfected D1 were used. The pK5/OVA-and pCMV/EGFP-transfected D1 were used as negative controls. The transfection procedure using electroporation resulted in maturation of the D1 cells as evidenced by the upregulation of maturation markers (data not shown). pDC-STAMP/OVA-transfected D1 cells induced the strong expansion of OT-I cells as evidenced by the dilution of the CFSE label ( Figure 5 ). Both positive controls also induced a large expansion of transferred OT-I and the negative control, D1 cells transfected with pCMV/EGFP, did not stimulate any detectable amounts of proliferation. pK5/OVA-transfected D1 cells showed a slight background proliferation. In conclusion, these results indicate that pDC-STAMP/OVA-transfected DCs have the capacity to process and present transfected antigens in vivo.
Detectable tumor protection after tattoo vaccination with pDC-STAMP/OVA Several methods exist to administer DNA in vivo via the skin. The skin is an ideal location for DNA vaccination because of the abundance of DCs. 15 The epidermis is rich in Langerhans cells and the dermal region contains dermal DCs. Both of these antigen presenting cells were putative targets for our DC-directed DNA constructs. Another method that targets cutaneous DCs is the tattooing of DNA. 18, 29, 31 Using a relatively low amount of DNA (30 mg), tattooing induces strong cellular and humoral responses against antigens driven by ubiquitous promoters like pCMV.
Following a similar protocol of tattooing a total of three times every 3 days, we tested our constructs directly in an in vivo tumor model. One day after the last tattoo treatment, OVA-transfected B16 melanoma cells were injected subcutaneously into the flank. As shown in Figure 6a , the pCMV/OVA-vaccinated mice were successfully protected against B16OVA tumor outgrowth confirming the effectiveness of this vaccination technique. Mice tattooed with pCMV/EGFP, however, quickly succumbed to tumor outgrowth, highlighting the necessity of OVA-encoding constructs to confer tumor protection to mice. The pDC-STAMP/OVA vaccination, though less effective than pCMV/OVA, significantly protected several mice from tumors, demonstrating that tattoo vaccination of DC-directed promoter constructs can generate a weak antigenspecific immunity.
Because DC-STAMP/OVA vaccination lead to the delay of tumor outgrowth, we investigated whether endogenous-specific CD8 þ T-cell formation could be detected using H-2K b tetramers complexed with the OVA peptide (257 --264). Fifteen days after the tattoo treatments, the lymph nodes draining the site of the tattoo were isolated and examined using fluorescent-activated cell sorting. pCMV/OVA vaccination lead to development of OVA peptide-specific CD8 þ T cells. However, as shown in Figure 6b , pDC-STAMP/OVA vaccination did not induce the production of detectible amounts of OVA-specific CD8 þ T cells.
Although, cellular responses were not detected with our assays, tattoo vaccination with pDC-STAMP/OVA significantly protected some mice from tumor outgrowth, indicating the induction of a weak but nonetheless detectable OVA-specific immune response.
DISCUSSION
DCs have a prominent role in initiating tumor-directed immune responses necessary for tumor immunotherapy. Currently, the emphasis in the clinic is on producing DCs ex vivo, loading them with relevant antigen and then administering them to cancer patients. However, this process is costly and labor intensive, thus alternative methods are being explored to target DCs in vivo with not only relevant tumor antigens but also with molecules capable of improving their pro-inflammatory qualities. Transcriptional targeting of DCs is one possible method to direct proteins to DCs in vivo. To achieve this, we have isolated the promoters of the DC-associated genes encoding CD11c, DC-SIGN, DC-STAMP and Langerin. Using several in vitro assays, we have confirmed that our promoter sequences are primarily active in DC cell lines and that the antigen produced can be processed and presented to T cells. The DC-STAMP promoter proved to be the most potent, as it had the highest activity and led to both CD8 þ and CD4 þ T-cell responses in vitro and demonstrated in vivo potential. Thus, we have developed a set of tools that can be used to both target DCs to generate antigen-specific immunity and to, on a wider scale, modulate DC function when proteins, such as signal transducers or cytokines, are encoded.
Developing sufficient immunity against tumor-related antigens is essential for tumor immunotherapy. However, typical tumor antigens are also found on normal tissues and are considered selfantigens and it is difficult to develop immune responses against them. In models using cutaneous DNA vaccinations, combining pCMV with endogenous tumor antigen genes, protective immune responses have not been detected. 32 However, DC vaccinations with the same endogenous antigen are quite successful. 32 These data suggest that widespread expression of antigen is detrimental to the development of immunity against self-antigens. Thus, the transcriptional targeting of DCs could be advantageous in this setting, especially in the priming phase of an immune response, 30 where one likes to avoid antigen expression by nonprofessional antigen presenting cells. Moreover, expression of vaccines limited to DC also improves their safety for clinical applications. One downside of transcriptional targeting of DCs via DC-specific promoters is the low transfection efficiency of DCs following in vivo vaccination. Furthermore, it has been shown previously that the strength of the antigen expression is of high importance in driving the specific immune response, 1 indicating that next to DCspecificity also expression levels are important. We were consistently unable to detect EGFP þ cells within the skin or lymph nodes after tattooing with our pDC-STAMP/OVA construct (data not shown). This could be the result of many factors, including poor in vivo transfection and especially low expression, which has been previously reported for cutaneous DNA vaccination. 2, 3 However, this appears not to be a huge obstacle to stimulating specific immune responses. It was shown before that very few transfected DCs are able to generate sufficient immune responses. Promoter activity is also essential for the development of strong immune responses to transfected antigens. Of the other DCassociated promoters that have been described in the literature (fascin, 20 dc-stamp, 23 cd11c, 33 dectin-2 19 and the promoter for murine MHC class II 34 ), the fascin promoter appears the most promising because of its high activity. Fascin promoter constructs are capable of inducing humoral and cellular responses after in vivo gene-gun vaccination to the same extent as those caused by CMV-driven constructs. 21 This is largely a consequence of its activity in matured DCs. Like the pCMV promoter, the fascin promoter increases its activity as a result of DC maturation, 35, 36 resulting in large amounts of antigen production. Of our isolated DC-associated promoters, the DC-STAMP promoter was the most efficient in driving antigen expression in D1 cells as measured by EGFP fluorescence, which is likely the reason that it was able to induce the strongest in vitro proliferation of OVA-specific T cells. However, pDC-STAMP transcription appears to be lower after maturation (Figure 1c) , and electroporation itself induce only partial maturation of D1 cells (data not shown). In contrast to pDC-STAMP, pCMV produced at least three times the amount of protein as determined by the mean fluorescence intensity of EGFP, allowing it to consistently outperform pDC-STAMP in both in vitro and in vivo assays.
That pDC-STAMP is functional in vivo and is supported by the ability of pDC-STAMP/OVA-transfected D1 to stimulate CD8 þ T-cell proliferation after adoptive transfer and by the fact that we detected a significant delay in tumor outgrowth after in vivo vaccination. Despite multiple attempts, we were unable to detect specific CD8 þ T-cell development or specific CD8 þ or CD4 þ T-cell proliferation (data not shown) following pDC-STAMP/OVA vaccination. However, the detection of specific cellular responses is not always detected concomitantly with tumor regression. 37 The limited capacity of the DC-specific promoters used in this study to induce immunity may be related to the relatively low expression levels they induce in DC. Increasing their strength by adding enhancer-type elements like those recognized by CIITA (class II, major histocompatibility complex, transactivator) might be important to improve their activity.
Vaccination by tattooing was employed as it has the potential to be an inexpensive and easily portable method to administer DNA. As it is a relatively novel method of dermal DNA vaccination, it could be argued that more traditional and widely tested methods will be more successful in combination with our constructs. Moreover, pDC-STAMP/OVA vaccination with several alternative methods of DNA vaccination (intramuscular, subcutaneous injection and gene gun) yielded similar or worse results in the tumor setting (data not shown). Therefore, it is essential to find ways to boost the immune response of pDC-STAMP/OVA after tattoo vaccination. To this end, we plan to examine the use of a prime-boost strategy, which is known to greatly increase the potency of DNA vaccinations. 38, 39 Previously Dresch et al. 13 have showed that lentiviral vector containing the 5 0 untranslated region of DC-STAMP yields long-term, DC-specific OVA expression in vivo. Moreover, their work confirms our data with respect to DC-STAMP promoter. 13 To transcriptionally target DCs, we have isolated several novel promoters that have a DC-specific activity and are capable of driving antigen expression. Although we have focused on the induction of immunity by permissive expression of relevant antigen in DC, the additional introduction of signal transducers or cytokines using the same techniques may favorably influence the behavior of DCs. Using these strategies, it may be possible to develop methods to use DNA vaccination in the treatment of cancer patients.
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